Novel combination treatment of type 2 diabetes DPP-4 inhibition + metformin

References

• AhrénBVildagliptin: an inhibitor of dipeptidyl peptidase-4 with antidiabetic propertiesExp Opin Invest Drugs20061543142
   PubMed Web of Science ®Google Scholar
• AhrénBDipeptidyl peptidase-4 inhibitors – clinical data and clinical implicationsDiabetes Care2007a30134450
   PubMed Web of Science ®Google Scholar
• AhrénBBarnettABaileyCDPP-4 inhibitorsBest practice and research: clinical endocrinology and metabolism; novel therapies of diabetes2007b
   Google Scholar
• AhrénBPaciniGImpaired adaptation of first-phase insulin secretion in postmenopausal women with glucose toleranceAm J Physiol1997273E70179357798
   PubMed Web of Science ®Google Scholar
• AhrénBSimonssonELarssonHInhibition of dipeptidyl peptidase IV improves metabolic control over a 4 week study period in type 2 diabetesDiabetes Care2002258697511978683
   PubMed Web of Science ®Google Scholar
• AhrénBSchmitzOGLP-1 receptor agonists and DPP-4 inhibitors in the treatment of type 2 diabetesHorm Metab Res2004368677615655721
   PubMed Web of Science ®Google Scholar
• AhrénBGomisRStandlETwelve- and 52-week efficacy of the dipeptidyl peptidase IV inhibitor LAF237 in metformin-treated patients with type 2 diabetesDiabetes Care2004a27287480
   PubMed Web of Science ®Google Scholar
• AhrénBLandin-OlssonMJanssonPAInhibition of dipeptidyl peptidase-4 reduces glycemia sustains insulin levels and reduces glucagon levels in type 2 diabetesJ Clin Endocrinol Metab2004b89207884
   PubMed Web of Science ®Google Scholar
• AhrénBFoleyJEPaciniGImproved meal-related β-cell function and insulin sensitivity by the dipeptidyl peptidase-IV inhibitor vildagliptin in metformin-treated patients with type 2 diabetes over 1 yearDiabetes Care20052819364016043735
   PubMed Web of Science ®Google Scholar
• AhrénBPaciniGTuraAImproved meal-related insulin processing contributes to the enhancement of B-cell function by the DPP-4 inhibitor vildagliptin in patients with type 2 diabetesHorm Metab Res200739826917992639
   PubMed Web of Science ®Google Scholar
• AschnerPKipnesMSLuncefordJKEffect of the dipeptidyl peptidase-4 inhibitor sitagliptin as monotherapy on glycemic control in patients with type 2 diabetesDiabetes Care2006292632717130196
   PubMed Web of Science ®Google Scholar
• BaileyCJTurnerRCMetforminN Engl J Med199633457498569826
   PubMed Web of Science ®Google Scholar
• BalasBBaigMRWatsonCThe dipeptidyl peptidase IV inhibitor vildagliptin suppresses endogenous glucose production and enhances islet function after single-dose administration in type 2 diabetic patientsJ Clin Endocrinol Metab20079212495517244786
   PubMed Web of Science ®Google Scholar
• BosiECamisascaRPColloberCEffects of vlidagliptin on glucose control over 24 weeks in patients with type 2 diabetes inadequately controlled with metforminDiabetes Care200730890517277036
   PubMed Web of Science ®Google Scholar
• BrazgRXuLDalla ManCEffect of adding sitagliptin, a dipeptidyl peptidase-4 inhibitor, to metformin on 24-h glycaemic control and β-cell function in patients with type 2 diabetesDiabetes Obes Metab200791869317300594
   PubMed Web of Science ®Google Scholar
• BredaECobelliCInsulin secretion rate during glucose stimuli: alternative analyses of C-peptide dataAnn Biomed Eng20012969270011556725
   PubMed Web of Science ®Google Scholar
• CharbonnelBSchernthanerGBrunettiPLong-term efficacy and tolerability of add-on pioglitazone therapy to failing monotherapy compared with addition of gliclazide or metformin in patients with type 2 diabetesDiabetes2005481093104
   Google Scholar
• CharbonnelBWuMKarasikAEfficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin added to ongoing metformin therapy in patients with type 2 diabetes inadequately controlled with metformin aloneDiabetes Care20062926384317130197
   PubMed Web of Science ®Google Scholar
• ConsoliAGomisRHalimiSInitiating oral glucose-lowering therapy with metformin in type 2 diabetic patients: an evidence-based strategy to reduce the burden of late-developing diabetes complicationsDiabetes Metab2004305091615671920
   PubMed Web of Science ®Google Scholar
• DeaconCFDipeptidyl peptidase 4 inhibition with sitagliptin: a new therapy for type 2 diabetesExp Opin Invest Drugs20071653345
   PubMed Web of Science ®Google Scholar
• DeFronzoRHissaMBlauwetMBSaxagliptin added to metformin improves glycemic control in patients with type 2 diabetesDiabetes200756Suppl 1A74
   Google Scholar
• DeFronzoRAPathogenesis of type 2 diabetes mellitusMed Clin North Am20048878783515308380
   PubMed Web of Science ®Google Scholar
• DeFronzoRARatnerREHanJEffects of exenatide (exendin-4) on glycemic control and weight over 30 weeks in metformin-treated patients with type 2 diabetesDiabetes Care200528109210015855572
   PubMed Web of Science ®Google Scholar
• Del PratoSPulizziNThe place of sulfonylureas in the therapy for type 2 diabetes mellitusMetabolism200655S20716631807
   PubMed Web of Science ®Google Scholar
• DerosaSGaddiAVPiccinniMNDifferential effect of glimepiride and rosiglitazone on metabolic control of type 2 diabetic patients treated with metformin: a randomized double-blind, clinical trialDiabetes Obes Metab2006819720516448524
   PubMed Web of Science ®Google Scholar
• DonnellyLAFoneyASFHattersleyATThe effect of obesity on glycaemic response to metformin or sulphonylureas in type 2 diabetesDiabetic Med2006231283316433709
   PubMed Web of Science ®Google Scholar
• DruckerDJNauckMAThe incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetesLancet2006368169670517098089
   PubMed Web of Science ®Google Scholar
• DunningBEFoleyJAhrénBAlpha-cell function in health and disease: influence of GLP-1Diabetologia20054817001316132964
   PubMed Web of Science ®Google Scholar
• fenglosMMSaadMFPi-SinyerFXEffects of liragflutide (NN2211) , a long-acting GLP-1 analogue, on glycaemic control and bodyweight in subjects with type 2 diabetesDiabet Med20052210162316026367
   PubMed Web of Science ®Google Scholar
• FonsecaVSchweizerAAlbrechtDAddition of vildagliptin to insulin improves glycaemic control in type 2 diabetesDiabetologia20075011485517387446
   PubMed Web of Science ®Google Scholar
• GallwitzBReview of sitagliptin phosphate: a novel treatment for type 2 diabetesVasc Health Risk Manag200732031017580730
   PubMedGoogle Scholar
• GarberAJSchweizerABaronMAVildagliptin in combination with pioglitazone improves glycaemic control in patients with type 2 diabetes failing thiazolidinedione monotherapy: a randomized, placebo-controlled studyDiabet Obes Metab2007916674
   PubMed Web of Science ®Google Scholar
• GinnarelliRAragonaMCoppelliAReducing insulin resistance with metformin: the evidence todayDiabetes Metab2003296S283514502098
   PubMed Web of Science ®Google Scholar
• GoldsteinBJFeinglosMNLuncefordJKEffect of initial combination therapy with sitagliptin, a dipeptidyl peptidase-4 inhibitor, and metformin on glycemic control in patients with type 2 diabetesDiabetes Care20073019798717485570
   PubMed Web of Science ®Google Scholar
• GreenJBFeinglosMNAre sulphonylureas passé?Curr Diabet Rep200763737
   Google Scholar
• GutzwillerJPDreweJGökeBGlucagon-like peptide-1 promotes satiety and reduces food intake in patients with diabetes mellitus type 2Am J Physiol1999276R1541410233049
   PubMed Web of Science ®Google Scholar
• HermanGABergmanAYiBTolerability and pharmacokinetics of metformin and the dipeptidyl peptidase 4 inhibitor sitagliptin when co-administered in patients with type 2 diabetesCurr Med Res Opin20062219394717022853
   PubMed Web of Science ®Google Scholar
• HinkeSAKuhn-WacheKHoffmanTMetformin effects on dipeptidylpeptidase IV degradation of glucagon-like peptide-1Biochem Biophys Res Commun20022911302811883961
   PubMed Web of Science ®Google Scholar
• HolstJJDeaconCFInhibition of the activity of dipeptidyl-peptidase IV as a treatment for type 2 diabetesDiabetes1998471663709792533
   PubMed Web of Science ®Google Scholar
• HundalRSInzucchiSEMetformin: new understandings, new usesDrugs20036318799412930161
   PubMed Web of Science ®Google Scholar
• IkedaTIwataKMurakamiHInhibitory effect of metformin on intestinal glucose absorption in the perfused rat intestineBiochem Biopharmacol20005988790
   PubMed Web of Science ®Google Scholar
• InzucchiSEOral antihyperglycemic therapy for type 2 diabetes: scientific reviewJAMA20022873607211790216
   PubMed Web of Science ®Google Scholar
• KahnSEThe importance of beta-cell failure in the development and progression of type 2 diabetesJ Clin Endocrinol Metab20018640475811549624
   PubMed Web of Science ®Google Scholar
• KahnSEHaffnerSMHelseMAGlycemic durability of rosiglitazone, metformin, or glyburide monotherapyN Engl J Med200635524274317145742
   PubMed Web of Science ®Google Scholar
• KarasikAWuMWilliams-HermanDSitagliptin added to ongoing metformin therapy provides sustained glycemic control over 54 weeks, with a low incidence of hypoglycaemia and with weight lossDiabetes200756Suppl 1A139
   Google Scholar
• KatzANambiSSMatherKQuantitative insulin sensitivity check index: a simple, accurate method for assessing insulin sensitivity in humansJ Clin Endocrinol Metab20078524021010902785
   PubMedGoogle Scholar
• KimDWangLBeconiM(2R)-4-oxo-4-[3-(trifluoromethyl)-5,6-dihydro[1,2,4]triazol[4,3,a]pyrazin-7(8H)-yl]-1-(2,4,5-trifluorophenyl)butan-2-amine: a potent, orally active dipeptidyl peptidase IV inhibitor for the treatment of type 2 diabetesJ Med Chem2005481415115634008
   PubMed Web of Science ®Google Scholar
• LeverveKMGuigasBDetailleDMitochondrial metabolism and type-2 diabetes: a specific target of metforminDiabetes Metab2003296S889414502105
   PubMed Web of Science ®Google Scholar
• LevetranCOral antidiabeti agents in type 2 diabetesCurr Med Res Opin2007239455217407651
   PubMed Web of Science ®Google Scholar
• LindsayJRDuffyNAMcKillopAMInhibition of dipeptidyl peptidase IV activity by oral metformin in type 2 diabetesDiabet Med200522654715842525
   PubMed Web of Science ®Google Scholar
• MannucciEPierazzuoliEOgnibeneAEffect of metformin on glucagon-like peptide 1 (GLP-1) and leptin levels in obese nondiabetic subjectsDiabetes Care2001244899411289473
   PubMed Web of Science ®Google Scholar
• MariAPaciniGMurphyEA model-based method for assessing insulin sensitivity from the oral glucose tolerance testDiabetes Care2001245394811289482
   PubMed Web of Science ®Google Scholar
• MariASallasWMHeYLVildagliptin, a dipeptidyl peptidase-IV inhibitor, improves model-assessed beta-cell function in patients with type 2 diabetesJ Clin Endocrinol Metab20059048889415886245
   PubMed Web of Science ®Google Scholar
• MatsudaMDeFronzoRAInsulin sensitivity indices obtained from oral glucose tolerance testing: comparison with the euglycemic insulin clampDiabetes Care19992214627010480510
   PubMed Web of Science ®Google Scholar
• MatthewsDRHoskerJPRudenskiASHomeostasis model assessment: insulin resistance and beta cell function from fasting plasma glucose and insulin concentrations in manDiabetologia198528412193899825
   PubMed Web of Science ®Google Scholar
• MentleinRDipeptidyl-peptidase IV (CD26) – role in the inactivation of regulatory peptidesRegul Pept19998592410588446
   PubMed Web of Science ®Google Scholar
• MigoyaEMMillerJLarsonPSitagliptin, a selective DPP-4 inhibitor, and metformin have complementary effects to increase active GLP-1 concentrationsDiabetes200756Suppl 1A74
   Google Scholar
• NathanDMBuseJBDavidsonMBManagement of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy. A consensus statement from the American Diabetes Association and the European Association for the Study of DiabetesDiabetes Care20062919637216873813
   PubMed Web of Science ®Google Scholar
• NauckMANiedereichholzUEttlerRGlucagon-like peptide-1 inhibition of gastric emptying outweighs its insulinotropic effects in healthy humansAm J Physiol199736E98189374685
   PubMedGoogle Scholar
• NauckMAMeiningerGShengDEfficacy and safety of the dipeptidyl peptidase-4 inhibitor, sitagliptin, compared with the sulfonylurea, glipizide, in patients with type 2 diabetes inadequately controlled on metformin alone: a randomized double-blind, non-inferiority trialDiabet Obes Metab20079194205
   PubMed Web of Science ®Google Scholar
• NissenSEWolskiKEffect of rosiglitazoine on the risk of myocardial infarction and death from cardiovascular causesN Engl J Med200735624577117517853
   PubMed Web of Science ®Google Scholar
• PerfettiRHuiHThe role of GLP-1 in the lifeand death of pancreatic beta cellsHorm Metab Res2004368041015655712
   PubMed Web of Science ®Google Scholar
• PratleyREJauffret-KamelSTwelve-week monotherapy with the DPP-4 inhibitor vildagliptin improves glycemic control in subjects with type 2 diabetesHorm Metab Res20063874233816823726
   PubMed Web of Science ®Google Scholar
• RazIHanefeldMXuLEfficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin as monotherapy in patients with type 2 diabetes mellitusDiabetologia20064925647117001471
   PubMed Web of Science ®Google Scholar
• RisticSByiersSFoleyJImproved glycaemic control with dipeptidyl peptidase-4 inhibition in patients with type 2 diabetes: vildagliptin (LAF237) dose responseDiabet Obes Metab200576928
   PubMed Web of Science ®Google Scholar
• RosenstockJBrazgRAndryukPJEfficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin added to ongoing pioglitazone therapy in patients with type 2 diabetes: a 24-week multicenter, randomized, double-blind, placebo-controlled, parallel-group studyClin Ther20062815566817157112
   PubMed Web of Science ®Google Scholar
• RosenstockJBaronMACamisascaRPEfficacy and tolerability of initial combination therapy with vildagliptin and pioglitazone compared with component monotherapy in patients with type 2 diabetesDiabetes Obes Metab200791758517300593
   PubMed Web of Science ®Google Scholar
• SchweizerACouturierAFoleyJEComparison between vildagliptin and metformin to sustain reductions in HbA1c over 1 year in drug-naïve patients with type 2 diabetesDiabet Med2007249556117509069
   PubMed Web of Science ®Google Scholar
• ScottRWuMSanchezMEfficacy and tolerability of the dipeptidyl peptidase-4 inhibitor sitagliptin as monotherapy over 12 weeks in patients with type 2 diabetesInt J Clin Pract2007611718017156104
   PubMed Web of Science ®Google Scholar
• SetterSMIltzJLThamsJMetformin hydrochloride in the treatment of type 2 diabetes mellitus: a clinical review with a focus on dual therapyClin Ther2003252991302614749143
   PubMed Web of Science ®Google Scholar
• StrattonIMAdlerAINeilHAAssociation of glycaemia with macrovascular and microvascular complications of type 2 (UKPDS 35): prospective observational studyBr Med J20003214051210938048
   PubMed Web of Science ®Google Scholar
• StumvollMNurjhanNPerrielloGMetabolic effects of metformin in non-insulin-dependent diabetes mellitusN Engl J Med199533355047623903
   PubMed Web of Science ®Google Scholar
• UmpierrezGIssaMVlanjnicAGlimepiride versus pioglitazone combination therapy in subjects with type 2 diabetes inadequately controlled on metformin monotherapy: results of a randomized clinical trialCurr Med Res Opin200622751916684436
   PubMed Web of Science ®Google Scholar
• VellaABockGGieslerPDEffects of dipeptidyl peptidase 4 inhibition on gastrointestinal function, meal appearance and glucose metabolism in type 2 diabetesDiabetes20075614758017303799
   PubMed Web of Science ®Google Scholar
• VilsbøllTKrarupTMadsbadSDefective amplification of the late phase insulin response to glucose by GIP in obese type II diabetic patientsDiabetologia20024511111912189441
   PubMed Web of Science ®Google Scholar